GeoVax's AIDS (HIV-1) recombinant DNA and MVA vaccines were initially developed at Emory University by Dr. Harriet Robinson, currently GeoVax's Chief Scientific Officer, in collaboration with researchers at the NIAID (NIH) and the U.S. Centers for Disease Control (CDC).
Our focus is the development of AIDS vaccines comprising the major HIV-1 subtypes or clades (A, B and C). These vaccines can be used alone or in combination depending on a local infection. Our first priority is Clade B which is most common in North America, European Union, Japan and Australia.
When administered in series, our AIDS vaccines induce strong cellular and humoral immunity (protection) in non-human primates against multiple HIV-1 (AIDS virus) proteins. This suggests that GeoVax's vaccines will provide protection against the development of AIDS in HIV-1 virus infected people. Recently completed non-human studies provide data to indicate our vaccines will also prove an effective treatment for those already infected.
Clinical Progress / Milestones
Successful Completion: Initial Phase 1 Preventive Human Trial of a Prototype DNA
Successful Completion: Four Additional Phase 1 Preventive Human Trials Testing Different Regimens of DNA and MVA Vaccines
Successful Completion: Phase 2a Preventive Human Trial with DNA and MVA Vaccines
Launched / Vaccination Underway: Phase 1/2 Therapeutic Trial to Test Treatment Potential of Vaccines
Launched / Vaccination Underway: Phase 1 Preventive Trial to Test Second Generation GeoVax DNA Vaccine Using Adjuvant (GM-CSF) in Combination with MVA Vaccine.